EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Posting of Annual Report & Accounts

And Notice of Annal General Meeting

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, confirms that the Annual Report and Accounts for the year ended 31 December 2020 ("2020 Annual Report") and the Notice of the 2021 Annual General Meeting ("AGM") have now been published on the Company's website at:

https://www.ekfdiagnostics.com/documents-reports.html 

The 2020 Annual Report, the Notice of AGM and details voting by proxy  will be posted to shareholders who have not consented to receive electronic communications today, 23 April 2021.

The AGM is to be held on 19 May 2021 at 10.30am at the Company's offices at Avon House, 19 Stanwell Road, Penarth, Cardiff CF64 2EZ and will consider the Resolutions set out in the Notice of AGM.

Due to the UK Government restrictions on public gatherings as a consequence of the COVID-19 pandemic, it will not be possible for shareholders to attend the AGM in person. The Board, with this in mind and in accordance with the Corporate Insolvency and Governance Act 2020, has therefore decided that the AGM will be held as a 'closed' meeting with the minimum number of Directors and officers who hold shares, present, to form the necessary quorum. Regrettably, other shareholders will not be permitted to attend the meeting in person.

The Company will provide a facility for shareholders to join the AGM either online or telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that Shareholders register for the meeting and submit questions in advance, before 10.30 a.m. 17 May 2021.

To register for dial-in details and to submit any questions please contact Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933 8787.

Proxy voting

Shareholders will not receive a hard copy form of proxy for the 2021 AGM in the post. Instead, Shareholders will be able to vote electronically using the link www.signalshares.com. Proxy votes must be received no later than 10.30a.m. on 17 May 2021.

Shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.

EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products.